Phase II Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes on Patients With Unresectable Non Small Cell Lung Cancer Responding to Induction Chemotherapy
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival
4 months
Yes
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
IGR Dex2
NCT01159288
December 2009
December 2014
Name | Location |
---|